<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02817802</url>
  </required_header>
  <id_info>
    <org_study_id>C1503</org_study_id>
    <nct_id>NCT02817802</nct_id>
  </id_info>
  <brief_title>BIOTRONIKS - Safety and Performance in de NOvo Lesion of NatiVE Coronary Arteries With Magmaris- Registry: BIOSOLVE-IV</brief_title>
  <acronym>BIOSOLVE-IV</acronym>
  <official_title>BIOTRONIKS - Safety and Performance in de NOvo Lesion of NatiVE Coronary Arteries With Magmaris- Registry: BIOSOLVE-IV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The registry will investigate the clinical performance and long-term safety of Magmaris in a
      real world setting
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronary stents are the default devices for the treatment of coronary artery disease in
      percutaneous coronary intervention (PCI) according to existing guidelines. However,
      thrombosis and restenosis are still the main limitations of current permanent metallic
      stents. In contrast to Bare Metal Stents (BMSs), Drug Eluting Stents (DESs) have a reduced
      restenosis rate due to the presence of antiproliferative agents in the coating layer of the
      stent surface and reduced rate of repeat revascularisation. However, late and very late stent
      thrombosis remains the limitation of DES in spite of prolonged dual antiplatelet
      therapy.Bioabsorbable scaffolds have been introduced to overcome limitations of permanent
      metallic stents.

      The aim of this observational registry is to investigate the clinical performance and
      long-term safety of Magmaris in a real world setting.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Target Lesion Failure (TLF)* at 12 months</measure>
    <time_frame>12 month</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1065</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Magmaris</arm_group_label>
    <description>Magmaris Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magmaris</intervention_name>
    <description>PCI (Magmaris)</description>
    <arm_group_label>Magmaris</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with symptomatic coronary artery disease needing the treatment of de novo native
        coronary artery lesions.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is ≥18 years of age

          -  Subject must be willing to sign a Patient Informed Consent (PIC) or Patient Data
             Release Form (PDRF) where applicable

          -  Symptomatic coronary artery disease

          -  Target lesion stenosis by visual estimation: &gt; 50% - &lt; 100% and TIMI flow ≥1

          -  Subject is eligible for Dual Anti Platelet Therapy (DAPT)

        Exclusion Criteria:

          -  Pregnant and/or breast feeding females or females who intend to become pregnant during
             the time of the registry

          -  Known allergies to: Acetylsalicylic Acid (ASA), clopidogrel, ticlopidine, heparin or
             any other anticoagulant /antiplatelet required for PCI, contrast medium, sirolimus, or
             similar drugs; or the scaffold materials including Magnesium, Yttrium, Neodymium,
             Zirconium, Gadolinium, Dysprosium, Tantalum that cannot be adequately pre-medicated

          -  Subjects on dialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Verheye, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Institute Middelheim, Antwerpen, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Kang-Yin Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Elizabeth Hospital, Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Banu Eyueboglu Seitz, PhD</last_name>
    <email>banu.eyueboglu.seitz@biotronik.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Contilia Heart- and Vascular Center, Elisabeth Krankenhaus</name>
      <address>
        <city>Essen</city>
        <zip>45138</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas K Schmitz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thomas Schmitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiology, Pauls Stradins Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <zip>LV-1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrejs Erglis, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Andrejs Erglis, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Latvia</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2016</study_first_submitted>
  <study_first_submitted_qc>June 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2016</study_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Registry</keyword>
  <keyword>Magmaris</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>PCI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The primary outcome data will be shared after the publication of it.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

